Literature DB >> 3784442

[Clinical experiences following the surgical therapy of asymptomatic, oligosymptomatic and symptomatic parathyroid gland hyperfunction].

B Niederle, R Roka, J Kovarik, K Klaushofer, G Schernthaner, A Fritsch.   

Abstract

Depending on their symptomatology 152 cured (i.e., normocalcemic) patients with surgically proven primary hyperparathyroidism (pHPT) showed typical symptoms preoperatively. Besides hypercalcemia and elevated parathyroid hormone levels, 15 patients suffered only from hypertension and/or diffuse osteoporosis and/or complaints caused by the hypercalcemic syndrome (oligosymptomatic patients). Nine patients had no complaints (asymptomatic patients). The long-term clinical course of all patients was analyzed up to 22 years. Although the formation of urinary calculi was stopped in 94% of cases, a deterioration of renal function and hypertension was seen in symptomatic (12.5% and 9.2%, respectively) and oligosymptomatic patients (6.7% and 13.3%, respectively). Renal function and hypertension were unpredictable despite normalization of the hyperactive parathyroid metabolism and were of decisive prognostic significance; 6% died of acute or chronic renal failure, or of the consequences of hypertension. Multiple bone lesions, even large, healed functionally and were of no prognostic significance. In the majority of symptomatic patients gastrointestinal manifestations held postoperatively, but two patients died of acute pancreatitis without gastrointestinal complaints preoperatively. Almost all symptoms of the hypercalcemic syndrome disappeared immediately and permanently in symptomatic and oligosymptomatic patients. No deterioration of renal function and no elevation of blood pressure was observed in cured asymptomatic patients postoperatively. Immediate surgical treatment even in asymptomatic patients may have avoided complications of chronic renal failure or of hypertension. As soon as organic manifestations, even in a mild form, have been established, it seems impossible to predict the course and to prevent an unfavorable clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3784442     DOI: 10.1007/bf01728615

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  17 in total

1.  Primary hyperparathyroidism. Clinical and structural findings in 138 cases.

Authors:  J HELLSTROM; B I IVEMARK
Journal:  Acta Chir Scand Suppl       Date:  1962

2.  Hypertension in hyperparathyroidism.

Authors:  J HELLSTROM; G BIRKE; C A EDVALL
Journal:  Br J Urol       Date:  1958-03

Review 3.  Primary hyperparathyroidism.

Authors:  L N Pyrah; A Hodgkinson; C K Anderson
Journal:  Br J Surg       Date:  1966-04       Impact factor: 6.939

4.  Primary hyperparathyroidism diagnosed at autopsy. A study of eight cases.

Authors:  J N Webb; V Crucioli; A Gordon
Journal:  Scott Med J       Date:  1983-10       Impact factor: 0.729

5.  The state of health of patients previously operated on for primary hyperparathyroidism compared with randomized controls.

Authors:  H Ronni-Sivula
Journal:  Ann Chir Gynaecol       Date:  1985

6.  Hyperparathyroidism: experiences with treated and untreated patients.

Authors:  P G Rohl; M Wilkinson; P Clifton-Bligh; S Posen
Journal:  Med J Aust       Date:  1981-05-16       Impact factor: 7.738

7.  Progressive renal failure in surgically treated hyperparathyroidism.

Authors:  J Dixon; J F Smith
Journal:  J Clin Pathol       Date:  1981-07       Impact factor: 3.411

8.  Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community.

Authors:  H Heath; S F Hodgson; M A Kennedy
Journal:  N Engl J Med       Date:  1980-01-24       Impact factor: 91.245

9.  Reversible hypertension in primary hyperparathyroidism--pre- and posteroperative blood pressure in 75 cases.

Authors:  J D Ringe
Journal:  Klin Wochenschr       Date:  1984-05-15

10.  Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests.

Authors:  F W Lafferty
Journal:  Arch Intern Med       Date:  1981-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.